Interferon News and Research

RSS

EASL to present online HCV management recommendations at the ILCTM

The European Association for the Study of the Liver (EASL) will this week be announcing new on-line recommendations on the management of hepatitis C (HCV) at the International Liver Congress- (ILC).

9 Apr 2014

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Bristol-Myers Squibb Company (NYSE:BMY) announced today that they have submitted new drug applications (NDAs) with the U.S. Food and Drug Administration (FDA) for the investigational products daclatasvir (DCV), an NS5A replication complex inhibitor, and asunaprevir (ASV), a NS3 protease inhibitor.

8 Apr 2014

Sanford-Burnham to present new cancer research data at AACR 2014

Sanford-Burnham Medical Research Institute will present a wide range of new research data at the annual American Association for Cancer Research Meeting in San Diego starting Saturday, April 5, at the San Diego Convention Center. The presentations will cover a variety of topics including breast, melanoma, and prostate cancer, as well as novel methods of delivering drugs to tumors.

4 Apr 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Janssen R&D Ireland (Janssen) announced today that two Phase 3 trials are recruiting patients to examine the efficacy and safety of the NS3/4A protease inhibitor simeprevir in combination with the nucleotide inhibitor sofosbuvir for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection in treatment-naive and treatment-experienced patients with and without cirrhosis.

3 Apr 2014

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Gilead Sciences, Inc. today announced topline results from a Phase 3 clinical trial (Study GS-US-334-0118) in Japan evaluating the once-daily nucleotide analog polymerase inhibitor sofosbuvir in combination with ribavirin (RBV) for the treatment of genotype 2 chronic hepatitis C virus (HCV) infection.

3 Apr 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Medivir AB announced today that the Russian Ministry of Health has approved Sovriad (simeprevir) for the treatment of chronic hepatitis C genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adults with compensated liver disease (including cirrhosis) who are treatment naïve or who have failed previous interferon therapy (pegylated or non-pegylated) with or without ribavirin. Russia will be the first country within EMEA to gain access to simeprevir, which represents a significant advance in hepatitis C treatment.

24 Mar 2014

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Genzyme, a Sanofi company, announced today that Brazil's national health surveillance agency, ANVISA, has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS) to slow or reverse the accumulation of physical disability and reduce the frequency of clinical exacerbations.

21 Mar 2014

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers at UC Davis have found that the investigational cancer vaccine tecemotide, when administered with the chemotherapeutic cisplatin, boosted the immune response and reduced the number of tumors in mice with lung cancer.

20 Mar 2014

Researchers Study how Marburg virus and host protein interaction help in developing inhibitors of virus

A protein that normally protects cells from environmental stresses has been shown to interact Marburg virus VP24, allowing the deadly Marburg virus to live longer and replicate better, according to a cell culture study led by scientists at the Icahn School of Medicine at Mount Sinai.

14 Mar 2014

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Aeras today announced the initiation of the first randomized, controlled tuberculosis (TB) vaccine trial designed to study prevention of Mycobacterium tuberculosis (Mtb) infection by vaccination.

11 Mar 2014

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Today Boehringer Ingelheim announced results from STARTVerso4 in patients with HCV/HIV co-infection. Hepatitis C viral cure 12 weeks after the conclusion of treatment (SVR12) was achieved by 72% of all patients in the trial. Patients were enrolled in either 120mg or 240mg faldaprevir dose groups.

6 Mar 2014

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

Chronic hepatitis C virus (HCV) infection can lead to serious diseases such as cirrhosis and cancer of the liver, so viral clearance and prevention of relapse are important treatment goals.

6 Mar 2014

3D structure of enzyme helps defend against bacteria

An essential weapon in the body's fight against infection has come into sharper view. Researchers at Princeton University have discovered the 3D structure of an enzyme that cuts to ribbons the genetic material of viruses and helps defend against bacteria.

3 Mar 2014

Advanced age should not preclude sunitinib use for mRCC

Elderly kidney cancer patients benefit from sunitinib therapy just as much as their younger counterparts, a retrospective analysis of six clinical trials shows.

21 Feb 2014

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

PBL Assay Science announces a licensing agreement with HumanZyme, Inc. (Chicago, USA) to expand reagent offerings. The agreement allows PBL to provide ~50 authentic human cell-expressed (HCE) cytokines and growth factors directly to scientists worldwide.

From PBL Assay Science 20 Feb 2014

Researchers identify new type of regulatory blood cells that can combat brain inflammation

Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune cells called T-cells induce chronic inflammation and degeneration of the brain. Researchers at BRIC, the University of Copenhagen, have identified a new type of regulatory blood cells that can combat such hyperactive T-cells in blood from patients with multiple sclerosis. By stimulating the regulatory blood cells, the researchers significantly decreased the level of brain inflammation and disease in a biological model.

17 Feb 2014

Study findings suggest potential targets for treating HCV

The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus' attempt to weaken the attack on it.

11 Feb 2014

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for a once-daily fixed-dose combination of the NS5A inhibitor ledipasvir (LDV) 90 mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400 mg for the treatment of chronic hepatitis C genotype 1 infection in adults.

11 Feb 2014

Long-distance signaling molecules tell brain to produce anti-viral interferon

The brain contains a defense system that prevents at least two unrelated viruses-and possibly many more-from invading the brain at large. The research is published online ahead of print in the Journal of Virology.

11 Feb 2014

Interferon News and Research

EASL to present online HCV management recommendations at the ILCTM

Bristol-Myers Squibb submits NDAs to FDA for treatment of genotype 1b hepatitis C

Sanford-Burnham to present new cancer research data at AACR 2014

Janssen begins Phase 3 OPTIMIST trials for treatment of chronic Genotype 1 HCV infection

Gilead reports topline results from sofosbuvir Phase 3 trial in Japan for treatment of HCV infection

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Russian Ministry of Health approves Medivir's simeprevir for chronic hepatitis C genotype 1 infection

Brazil's ANVISA approves Genzyme's Lemtrada for multiple sclerosis treatment

Investigational vaccine reduces number of tumors in mice with lung cancer

Researchers Study how Marburg virus and host protein interaction help in developing inhibitors of virus

Controlled TB vaccine trial designed to study prevention of Mtb infection by vaccination

Boehringer Ingelheim reports results from SVR12 Phase 3 trial in patients with HCV/HIV co-infection

Low-dose oral interferon may reduce risk of HCV relapse in patients with mild liver fibrosis

3D structure of enzyme helps defend against bacteria

Advanced age should not preclude sunitinib use for mRCC

PBL Assay Science, HumanZyme ink licensing agreement to expand reagent offerings

Researchers identify new type of regulatory blood cells that can combat brain inflammation

Study findings suggest potential targets for treating HCV

Gilead submits NDA to FDA for fixed-dose combination of ledipasvir and sofosbuvir for hepatitis C infection

Long-distance signaling molecules tell brain to produce anti-viral interferon

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News